SEC Form 3
FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person*
(Street)
| 2. Date of Event Requiring Statement (Month/Day/Year) 08/01/2018 | 3. Issuer Name and Ticker or Trading Symbol Aptevo Therapeutics Inc. [ APVO ] | |||||||||||||
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| 5. If Amendment, Date of Original Filed (Month/Day/Year) | ||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Beneficially Owned | |||
---|---|---|---|
1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock(1) | 74,505 | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Employee Stock Option (Right to Buy)(1) | (2) | 08/07/2020 | Common Stock | 2,650 | 1.63 | D | |
Employee Stock Option (Right to Buy)(1) | (3) | 03/10/2021 | Common Stock | 35,267 | 2.47 | D | |
Employee Stock Option (Right to Buy)(1) | (4) | 03/09/2022 | Common Stock | 28,441 | 2.55 | D | |
Employee Stock Option (Right to Buy)(1) | (5) | 08/09/2022 | Common Stock | 9,783 | 3.03 | D | |
Restricted Stock Unit(1)(6) | (7) | 08/09/2018 | Common Stock | 1,630 | (6) | D | |
Employee Stock Option (Right to Buy)(1) | (8) | 02/28/2026 | Common Stock | 40,614 | 2.97 | D | |
Restricted Stock Unit(1)(6) | (9) | 03/01/2019 | Common Stock | 6,787 | (6) | D | |
Employee Stock Option (Right to Buy) | (10) | 02/23/2027 | Common Stock | 17,500 | 1.96 | D | |
Employee Stock Option (Right to Buy) | (11) | 06/30/2027 | Common Stock | 17,500 | 2.15 | D | |
Employee Stock Option (Right to Buy) | (12) | 03/09/2028 | Common Stock | 35,000 | 3.13 | D |
Explanation of Responses: |
1. Each security was originally issued by Emergent BioSolutions Inc. and, as a result of the spin-off of the Issuer from Emergent BioSolutions Inc. effective on August 1, 2016, was adjusted and assumed by the Issuer, other than 41,497 shares of the Issuer's common stock that was issued in connection with the spin-off. |
2. The stock option was granted on August 8, 2013 and became exercisable in three equal annual installments beginning on August 7, 2014. |
3. The stock option was granted on March 11, 2014 and became exercisable in three equal annual installments beginning on March 10, 2015. |
4. The stock option was granted on March 10, 2015 and became exercisable in three equal annual installments beginning on March 9, 2016. |
5. The stock option was granted on August 10, 2015. 3,261 shares underlying the stock option became exercisable on each of August 9, 2016 and August 9, 2017, and the remaining 3,261 shares become exercisable on August 9, 2018. |
6. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
7. On August 10, 2015 the reporting person was granted 4,892 restricted stock units. 1,631 shares of common stock underlying the restricted stock units vested on each of August 9, 2016 and August 9, 2017, and the remaining 1,630 shares vest on August 9, 2018. |
8. The stock option was granted on March 1, 2016. 13,538 shares underlying the stock option became exercisable on each of February 28, 2017 and February 28, 2018, and the remaining 13,538 shares become exercisable on February 28, 2019. |
9. On March 1, 2016 the reporting person was granted 20,365 restricted stock units. 6,789 shares of common stock underlying the restricted stock units vested on each of March 1, 2017 and March 1, 2018, and the remaining 6,787 shares vest on March 1, 2019. |
10. The stock option was granted on February 24, 2017. 5,833 shares underlying the stock option became exercisable on February 23, 2018, 5,833 shares become exercisable on February 23, 2019 and 5,834 shares become exercisable on February 23, 2020. |
11. The stock option was granted on June 1, 2017. 5,833 shares underlying the stock option became exercisable on May 31, 2018, 5,833 shares become exercisable on May 31, 2019 and 5,834 shares become exercisable on May 31, 2020. |
12. The stock option was granted on March 10, 2018 and becomes exercisable in three equal annual installments beginning on March 9, 2019. |
Remarks: |
Exhibit List: Exhibit 24 - Power of Attorney |
/s/ Carl A. Valenstein, attorney-in-fact | 08/10/2018 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |